Moxalactam
This third-generation cephalosporin antibiotic with unusual oxacephem structure had good activity against gram-negative bacteria and anaerobes but was associated with serious bleeding problems due to interference with vitamin K-dependent clotting factors. It has been largely replaced by safer cephalosporins and other antibiotics.
Masse moléculaire
520,5000 g/mol
LogP
-0,60
TPSA
232,00 Ų
Règle des 5 de Lipinski
Non conforme
Mécanisme d'action
Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.
Structure 2D
Cite this structure
Embed this structure
SMILES
CO[C@@]1(NC(=O)C(C(=O)O)c2ccc(O)cc2)C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CO[C@@H]21
InChI
InChI=1S/C20H20N6O9S/c1-25-19(22-23-24-25)36-8-10-7-35-18-20(34-2,17(33)26(18)13(10)16(31)32)21-14(28)12(15(29)30)9-3-5-11(27)6-4-9/h3-6,12,18,27H,7-8H2,1-2H3,(H,21,28)(H,29,30)(H,31,32)/t12?,18-,20+/m1/s1
Molecular Formula
C20H20N6O9S
HBD / HBA
4 / 13
Liaisons Rotatives
9
Atomes Lourds
36
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
This third-generation cephalosporin antibiotic with unusual oxacephem structure had good activity against gram-negative bacteria and anaerobes but was associated with serious bleeding problems due to interference with vitamin K-dependent clotting factors. It has been largely replaced by safer cephalosporins and other antibiotics.
Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.
Yes, Moxalactam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL74632. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 47499. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="moxalactam"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/moxalactam/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/moxalactam/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/moxalactam/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="moxalactam"></drugfyi-drug>